Extended siponimod release <i>via</i> low-porosity PLGA fibres: a comprehensive three-month <i>in vitro</i> evaluation for neovascular ocular diseases-Reference-Cited by-同舟云学术

Extended siponimod release via low-porosity PLGA fibres: a comprehensive three-month in vitro evaluation for neovascular ocular diseases

Published:2024 Issue:18 Volume:12 Page:4823-4844
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Alshaikh Rasha A.¹²^ORCID,Chullipalliyalil Krishnakumar³,Waeber Christian¹⁴^ORCID,Ryan Katie B.¹⁵^ORCID

Affiliation:

1. School of Pharmacy, University College Cork, Cork, Ireland

2. Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt

3. Centre for Advanced Photonics & Process Analysis, Munster Technological University Cork, T12 P928 Cork, Ireland

4. Department of Pharmacology and Therapeutics, School of Medicine, University College Cork, Cork, Ireland

5. SSPC The SFI Research Centre for Pharmaceuticals, School of Pharmacy, University College Cork, Cork, Ireland

Abstract

The sustained release of siponimod from low-porosity electrospun PLGA fibers offers an alternative treatment for ocular neovascular diseases, potentially reducing intravitreal injection frequency to fewer than four injections per year.

Funder

Irish Research Council for Science, Engineering and Technology

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/BM/D4BM00339J

Reference80 articles.

1. Projected prevalence of age-related macular degeneration in Scandinavia 2012-2040

2. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study

3. Ocular neovascularization

4. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies

5. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review